ArticleIrish journal of medical science2022

Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study.

Satilmis Bilgin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.